BackAcura Pharmaceuticals Overview

Acura Pharmaceuticals Other Current Liabilities

Track Acura Pharmaceuticals's other current liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$0.00

Peer trimmed avg / median

Loading

Acura Pharmaceuticals Other Current Liabilities History

Loading

Acura Pharmaceuticals vs. peers: Other Current Liabilities Comparison

Loading

Acura Pharmaceuticals Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Acura Pharmaceuticals (ACUR) FAQ

Acura Pharmaceuticals (ACUR) currently reports a other current liabilities of $0 as of September 2023. In the prior-year period, the figure was $0. Use the charts on this page to explore Acura Pharmaceuticals's other current liabilities history and peer comparisons.

Acura Pharmaceuticals's other current liabilities changed from $0 to $0 (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acura Pharmaceuticals reported $0 in other current liabilities as of September 2023. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acura Pharmaceuticals, and consider following ACUR for alerts when major investors trade the stock.